Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

Trauma Clinical Trial

Official title:

Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01201863
• Other study ID #: 10 IHA 11650
• Status: Completed
• Phase: Phase 4
• Start date: September 2010
• Est. completion date: July 2014

Study information

• Verified date: July 2021
• Source: Craig Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to address 3 short term objectives; (1) Determine the effects of physiologic testosterone (T) therapy on neurological function and functional independence following traumatic brain injury (TBI) in hypogonadal men during inpatient rehabilitation; (2) Document the natural history of neuroendocrine dysfunction and recovery in men during inpatient rehabilitation after TBI; (3) Obtain data to validate the NIH toolbox, a novel assessment of neurological function for use in the TBI population; and 2 long-term objectives: (1) Utilize study findings to design a multicenter trial to further assess the impact of T therapy in hypogonadal men following TBI and (2) Impact TBI practice management with new information about neuroendocrine dysfunction after TBI and hormone treatments to improve outcomes.

Description:

This randomized, double blind, placebo-controlled pilot study assessed the hormonal status of men on admission to an inpatient TBI rehabilitation program. 498 consecutively admitted men for TBI rehabilitation were screened for participation in the study. 22 participants with low T who met all criteria were randomized into placebo (n=10), or physiologic T therapy (n=12). Of those with normal T who met all criteria, 24 were randomized into a follow up group. All participants were evaluated every two weeks for up to 12 weeks: hormone levels, FIM ratings and NIH Toolbox testing as able. There was participant drop out over time as participants were discharged from the hospital. The final analysis examined differences between the normal T, low T Treatment and low T placebo groups on hormone levels, FIM ratings and NIH Toolbox results at baseline and weeks 2, 4 and 6.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 16 Years to 65 Years

Eligibility

Inclusion Criteria:

1. History of TBI as defined as "damage to brain tissue caused by an external mechanical force as evidenced by loss of consciousness or post traumatic amnesia (PTA) due to brain trauma or by objective neurological findings that can be reasonably attributed to TBI on physical examination or mental status examination;"82

2. Moderate to severe TBI as indicated by a Glasgow Coma Scale (GCS) score of less than or equal to 12 at emergency department admission, or post traumatic amnesia (PTA) of greater than or equal to seven days post-injury, or radiographic evidence of intracranial injury;

3. Continuously hospitalized from time of injury until admission for rehabilitation;

4. Enrolled in study within 6 months of TBI;

5. Receiving inpatient rehabilitation for TBI at Craig Hospital;

6. Males between the ages of 16 to 65 (inclusive);

7. Approval by attending physician;

8. Testosterone level below the assay normal range;

9. Consent to study participation

Exclusion Criteria:

10. History of any conditions that would prohibit testing contained in the NIH toolbox;

11. Non-English or non-Spanish speaking (to the extent that would limit the ability to complete study measures);

12. History of prior psychiatric illness requiring hospitalization;

13. Prior testosterone therapy;

14. History of or current or suspected hormonally dependent cancer , including carcinoma of the breast or prostate cancer;

15. Known hypersensitivity to any T gel ingredients including alcohol and soy products;

16. Hematocrit (HCT) greater than 55% (normal range in Colorado is up to 52) or transaminase elevation >4x upper limit of the normal range.

17. Abnormal finding on digital rectal examination such as nodule, asymmetry, or induration (Does not include enlarged prostate or abnormal rectal tone)

18. PSA>4.0

19. BMI <16 or >40kg/m2

20. History of untreated prolactinoma

21. History of severe heart failure or uncontrolled medical problem that would interfere with the participant's safety in the study as determined by the investigator.

Related Conditions & MeSH terms

• Brain Injuries
• Brain Injuries, Traumatic
• Brain Injury
• Endocrine Dysfunction
• Trauma
• Wounds and Injuries

Intervention

Drug:
• Androgel (Testosterone Gel)
2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.

Other:
• Placebo gel
2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.

Locations

Country	Name	City	State
United States	Craig Hospital	Englewood	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
Craig Hospital	University of Colorado, Denver

Country where clinical trial is conducted

United States, 

References & Publications (1)

Ripley DL, Gerber D, Pretz C, Weintraub AH, Wierman ME. Testosterone replacement in hypogonadal men during inpatient rehabilitation following traumatic brain injury: Results from a double-blind, placebo-controlled clinical pilot study. NeuroRehabilitation — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Restricted Functional Independence Measure (FIM)	The FIM is the most widely accepted functional assessment measure in use in the rehabilitation community in the US. It is an 18-item ordinal clinician rating scale that is useful for assessment of functional skills progress during inpatient rehabilitation. It measures levels of independent/dependent performance of 13 motor functions and 5 cognitive functions. By adding the points for each item, the possible total score ranges from 18 to 126, with higher numbers indicating better performance. A restricted FIM total score that eliminated the toileting, bladder management and bowel management items was computed and used in the final analysis with scores ranging from 14-105). The restricted FIM total score was used as the primary outcome measure.	Administered at baseline and every other week for up to 12 weeks with 7 total possible administrations.

External Links

•   Pubmed link to Testosterone replacement in hypogonadal men during inpatient rehabilitation following traumatic brain injury